Corticosteroids and tocilizumab reduce in-hospital mortality in severe COVID-19 pneumonia: a retrospective study in a Spanish hospital

Autor: Gemma Navarro, M. Cervantes, Oriol Gasch, Aina Gomila, M L Machado, E Prieto, E Van den Eynde, J Oristrell, J C Oliva, L Falgueras, S Calzado, S Ortonobes, A Morón, Silvia Capilla, M. Navarro
Rok vydání: 2021
Předmět:
Male
0301 basic medicine
Microbiology (medical)
2019-20 coronavirus outbreak
Pediatrics
medicine.medical_specialty
Coronavirus disease 2019 (COVID-19)
030106 microbiology
Antibodies
Monoclonal
Humanized
Methylprednisolone
tocilizumab
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Tocilizumab
severe pneumonia
medicine
Corticosteroids
Humans
In patient
Hospital Mortality
030212 general & internal medicine
skin and connective tissue diseases
Aged
Retrospective Studies
General Immunology and Microbiology
In hospital mortality
business.industry
COVID-19
Retrospective cohort study
General Medicine
Middle Aged
medicine.disease
mortality
Hospitals
humanities
COVID-19 Drug Treatment
respiratory tract diseases
body regions
Pneumonia
Infectious Diseases
chemistry
Spain
Original Article
Female
business
Research Article
medicine.drug
Zdroj: Infectious Diseases (London, England)
article-version (VoR) Version of Record
ISSN: 2374-4243
2374-4235
DOI: 10.1080/23744235.2021.1884286
Popis: Background There is an urgent need to reduce mortality of COVID-19. We examined if corticosteroids and tocilizumab reduce risk for death in patients with severe pneumonia caused by SARS-CoV-2. Methods A retrospective cohort study was performed in a single university hospital. All adult patients admitted with confirmed severe COVID-19 pneumonia from 9 March to 9 April 2020 were included. Severe pneumonia was defined as multi-lobar or bilateral pneumonia and a ratio of oxygen saturation by pulse oximetry to the fraction of inspired oxygen (SpFi)
Databáze: OpenAIRE
Externí odkaz: